BPG is committed to discovery and dissemination of knowledge
Featured Articles
11/12/2020 4:09:15 AM | Browse: 1061 | Download: 1794
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 57419
Country China
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Meta-Analysis
Article Title Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis
Manuscript Source Unsolicited Manuscript
All Author List Li Yang, Xian-Zhe Dong, Xiao-Xuan Xing, Xiao-Hui Cui, Lin Li and Lan Zhang
Funding Agency and Grant Number
Funding Agency Grant Number
Beijing Hospitals Authority Ascent Plan DFL20190803
Capital Science and Technology Leading Talent Training Project Z191100006119017
National Nature and Science Foundation of China 81773778
China Postdoctoral Science Foundation 2019M650775
Corresponding Author Lan Zhang, PhD, Professor, Department of Pharmacy, Xuanwu Hospital of Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing Engineering Research Center for Nervous System Drugs, Beijing Institute for Brain Disorders, Key Laboratory for Neurodegenerative Diseases of Ministry of Education, No. 45 Changchun Street, Xicheng District, Beijing 100053, China. lanizhg@126.com
Key Words Gastric cancer; Gastroesophageal junction cancer; Anti-PD-1/anti-PD-L1 antibody therapy; Meta-analysis; Systematic review;
Core Tip Anti-PD-1/anti-PD-L1 antibody therapy, such as nivolumab and pembrolizumab, which has been approved by the FDA for marketing, enhances the body′s cellular immune response to anti-tumor effects by regulating T cell function. At present, it has become the first-line treatment for extensive stage small cell lung cancer and other cancers. In recent years, some clinical trials have also shown that anti-PD-1/anti-PD-L1 antibody therapy has a reliable effect in advanced gastric cancer or gastroesophageal junction cancer (GC/GEJC) patients, but there is still controversy. The main purpose of this review is to comprehensively evaluate the efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced GC/GEJC patients.
Publish Date 2020-11-12 03:59
Citation Yang L, Dong XZ, Xing XX, Cui XH, Li L, Zhang L. Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis. World J Gastrointest Oncol 2020; 12(11): 1346-1363
URL https://www.wjgnet.com/1948-5204/full/v12/i11/1346.htm
DOI https://dx.doi.org/10.4251/wjgo.v12.i11.1346
Full Article (PDF) WJGO-12-1346.pdf
Full Article (Word) WJGO-12-1346.docx